Cargando…

BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications

As the increased knowledge of tumour heterogeneity and genetic alterations progresses, it exemplifies the need for further personalized medicine in modern cancer management. Here, the similarities but also the differential effects of RAS and BRAF oncogenic signalling are examined and further implica...

Descripción completa

Detalles Bibliográficos
Autores principales: Oikonomou, Eftychia, Koustas, Evangelos, Goulielmaki, Maria, Pintzas, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322985/
https://www.ncbi.nlm.nih.gov/pubmed/25361007
_version_ 1782356471612178432
author Oikonomou, Eftychia
Koustas, Evangelos
Goulielmaki, Maria
Pintzas, Alexander
author_facet Oikonomou, Eftychia
Koustas, Evangelos
Goulielmaki, Maria
Pintzas, Alexander
author_sort Oikonomou, Eftychia
collection PubMed
description As the increased knowledge of tumour heterogeneity and genetic alterations progresses, it exemplifies the need for further personalized medicine in modern cancer management. Here, the similarities but also the differential effects of RAS and BRAF oncogenic signalling are examined and further implications in personalized cancer diagnosis and therapy are discussed. Redundant mechanisms mediated by the two oncogenes as well as differential regulation of signalling pathways and gene expression by RAS as compared to BRAF are addressed. The implications of RAS vs BRAF differential functions, in relevant tumour types including colorectal cancer, melanoma, lung cancer are discussed. Current therapeutic findings and future viewpoints concerning the exploitation of RAS-BRAF-pathway alterations for the development of novel therapeutics and efficient rational combinations, as well as companion tests for relevant markers of response will be evaluated. The concept that drug-resistant cells may also display drug dependency, such that altered dosing may prevent the emergence of lethal drug resistance posed a major therapy hindrance.
format Online
Article
Text
id pubmed-4322985
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-43229852015-02-10 BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications Oikonomou, Eftychia Koustas, Evangelos Goulielmaki, Maria Pintzas, Alexander Oncotarget Review As the increased knowledge of tumour heterogeneity and genetic alterations progresses, it exemplifies the need for further personalized medicine in modern cancer management. Here, the similarities but also the differential effects of RAS and BRAF oncogenic signalling are examined and further implications in personalized cancer diagnosis and therapy are discussed. Redundant mechanisms mediated by the two oncogenes as well as differential regulation of signalling pathways and gene expression by RAS as compared to BRAF are addressed. The implications of RAS vs BRAF differential functions, in relevant tumour types including colorectal cancer, melanoma, lung cancer are discussed. Current therapeutic findings and future viewpoints concerning the exploitation of RAS-BRAF-pathway alterations for the development of novel therapeutics and efficient rational combinations, as well as companion tests for relevant markers of response will be evaluated. The concept that drug-resistant cells may also display drug dependency, such that altered dosing may prevent the emergence of lethal drug resistance posed a major therapy hindrance. Impact Journals LLC 2014-10-21 /pmc/articles/PMC4322985/ /pubmed/25361007 Text en Copyright: © 2014 Oikonomou et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
spellingShingle Review
Oikonomou, Eftychia
Koustas, Evangelos
Goulielmaki, Maria
Pintzas, Alexander
BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
title BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
title_full BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
title_fullStr BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
title_full_unstemmed BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
title_short BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
title_sort braf vs ras oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322985/
https://www.ncbi.nlm.nih.gov/pubmed/25361007
work_keys_str_mv AT oikonomoueftychia brafvsrasoncogenesaremutationsofthesamepathwayequaldifferentialsignallingandtherapeuticimplications
AT koustasevangelos brafvsrasoncogenesaremutationsofthesamepathwayequaldifferentialsignallingandtherapeuticimplications
AT goulielmakimaria brafvsrasoncogenesaremutationsofthesamepathwayequaldifferentialsignallingandtherapeuticimplications
AT pintzasalexander brafvsrasoncogenesaremutationsofthesamepathwayequaldifferentialsignallingandtherapeuticimplications